• Explore /
  • Poster
  • / A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

Abstract Poster

Authors

Victor Moreno

V. Moreno Garcia

The Royal Marsden Hospital, Sutton, United Kingdom

V. Moreno Garcia , R. D. Baird , K. J. Shah , B. Basu , N. Tunariu , M. Blanco , P. A. Cassier , J. V. Pedersen , M. Puglisi , D. Sarker , D. Papadatos-Pastos , A. G. Omlin , A. Biondo , J. A. Ware , H. Koeppen , G. G. Levy , K. E. Mazina , J. S. De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics - Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

PI3-Akt-mTOR Pathway

Clinical Trial Registration Number

NCT00876122

Citation

J Clin Oncol 29: 2011 (suppl; abstr 3021)

Abstract #

3021

Poster Bd #

11

Abstract Disclosures

Similar Posters

First Author: Aurelius Gabriel Omlin

First Author: A. J. Wagner

First Author: Niamh Coleman

First Author: Juanita Suzanne Lopez